Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Oct 19;22:509. doi: 10.1186/s12964-024-01883-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 1 — Pr-MPO induces cell death in a wide range of cancer cell lines. A The top panel shows the structure of Pr-MPO (praseodymium (2-mercaptopyridine N-oxide) (dimethyl sulfoxide)). The lower panel shows the effect of a dose response of Pr-MPO on HeLa, MDA-MB-231 and SHEP-1 cells assessed by crystal violet staining. B Light microscope observation and C Colony forming assay of HeLa, MDA-MB-231 and SHEP-1 cells untreated or treated with Pr-MPO 5µM. Comparison of cell sensitivity assessed through crystal violet staining D of HCT116 p53 wild type or p53 KO to increasing concentrations of 5FU or Pr-MPO, E of HCT116 wild type and HCT1116 Bax^−/− Bak^−/− to increasing concentrations of 5FU, doxorubicin and Pr-MPO and F of A549 and 3CG to increasing concentrations of cisplatin and Pr-MPO. G Xenograft protocol used to assess the ability of DU145 cells to form tumors in nude mice (top panel) and pictures of tumors collected from control and Pr-MPO treated animals (lower panel). H Evolution of tumor volumes in control and Pr-MPO treated animals